Hemp Stocks

  • Marijuana Stocks Gaining Attention This Week


    Leon M

    an hour ago

    Marijuana Stocks Gaining Attention This Week (kann man wohl sagen - leider negative Attention)

    The Horizons’ Marijuana Life Sciences ETF (HMMJ) (HMLSF) is currently the largest and most representative marijuana exchange traded fund on the markets. The ETF attempts to duplicate, to an extent, the performance of the North American Marijuana Index, which was created to reveal the performance of a group of North American Life Sciences companies which have a large focus of their business in the marijuana industry.

    [Blocked Image: https://cdn-get.whotrades.com/u7/photoB939/20993285257-0/blogpost.jpeg]

    Since its initial trading date in April 2017, the marijuana ETF has yielded a return of about 46% and is still up nearly 30% over the last trailing year. For comparison, the SPDR S&P 500 ETF (SPY) gained about 15% during the same time period, while being up just 3.5% over the last year.

    Horizons’ Marijuana Life Sciences ETF’s Holdings Include:

    • Canopy Growth Corp. (CGC) (WEED)
    • Aurora Cannabis Inc. (ACB) (ACB.TO)
    • Tilray Inc. (TLRY)
    • Aphria Inc. (APHA) (APH)
    • GW Pharmaceuticals Plc. (GWPH)
    • Scotts Miracle Grow Co. (SMG)

    Click Here For Top Marijuana Stocks To Watch In December

  • Pot Stock Plunges 30% After Short Seller Exposes "Elaborate Shell Game"

    [Blocked Image: https://www.zerohedge.com/sites/default/files/styles/teaser_small/public/2018-12/2018.12.03aphria.JPG?itok=GrGylkdJ] 

    by Tyler Durden

    Mon, 12/03/2018 - 15:01

    It's been another volatile session for pot stocks broadly.

    [Blocked Image: https://www.zerohedge.com/sites/default/files/inline-images/2018-12-03_11-44-13.jpg]

    Day traders could be forgiven for feeling dazed and confused on Monday (for once, it may not have been due to overindulging in their favorite "commodity"). Shares of Tilray, Cronos and other pot stocks fluctuated between gains and losses - while shares of Aphria, another large Canadian pot stock plunged - following two scathing presentations from short sellers during a conference in New York City organized by famed short seller Whitney Tilson......

    .....Rounding out the day's pot stock-related news, Reuters reported that Altria was in "early stage" talks to acquire Cronos Group, another Canadian pot producer, as it seeks to diversify its holdings.

    Pot stocks have trended lower since Canada legalized recreational cannabis sales back in October. While the sector has largely suffered from a bubble-like influx of capital, concrete reports about a deal where an established beer or tobacco company buys a stake in a cannabis firm - like Constellation brands did with Canopy Growth - could send shares higher.

    • Dec 3, 2018 3:01 PM

    ....da wird nur so rumgeschupst...

  • ...gestern hoffte ich auf

    ...gestern hoffte ich auf eine Erholung da die Amis weg waren. Das Gegenteil zB Aurora nochmals fast 13% runter. Möchte gerne wissen wer/was dahinter steckt. Meine ehemaligen Gewinne haben sich mehr als aufgelöst. Dennoch wird immer wieder zum Einstieg getrommelt.....

  • Veröffentlichungen von professionellen Shortsellern, sind für mich Marktmanipulation auf höchstem Niveau. Sie lösen immer eine Verkaufspanik aus, auch wenn der Ansatz oft auch hanebüchen scheint. Wir kennen einige Beispiele für diese Praxis – Aurelius und Wirecard waren jüngst in Deutschland betroffen und nun hat es einen der “Big Five” in der Cannabis Branche erwischt. Aphria Inc (TSX/NYSE: APHA, WKN: A12HM0 / ISIN: CA03765K1049) wurde von Quintessential Capital Management gemeinsam mit Hindenburg Research in die Zange genommen. Die Veröffentlichung selbst scheint sehr gut recherchiert zu sein obwohl ich nicht meine Hand für sie ins Feuer legen werde. Sie sollten immer im Auge behalten, dass dieser Bericht einen Zweck verfolgt – der Kurs soll sinken! Je tiefer desto besser, denn umso mehr der Preis für die Aphira Aktie in die Knie geht umso mehr verdienen die Verfasser. Dieser “Skandal” färbt natürlich auf die gesamte Branche ab. Fast alle Cannabis Aktien mussten in den letzten Tagen mehr oder weniger Federn lassen außer der Cronos Group (TSX/NASDAQ: CRON, WKN: A2DMQY), die sich anscheinend mit dem Tabak Konzern Altria Group Inc. (NYSE: MO) in Gesprächen befinden. Für die “Marlboro News” war der Kursgewinn von 6% gestern eher gering.

    Minus 50% - Was ist da los? Geht der Musterknabe den Bach runter? Wie geht es weiter? | wallstreet-online.de - Vollständiger Artikel unter:

    Hallo Petra, die Sache mit Aphria und dem gesamten Sektor ist spannend. Für Aphria sieht es nicht gut aus. Kannst du alles im wallstreet-online.de verfolgen.

    Mal sehen, wie es weiter geht. Allgemein ist der Cann-Sektor überbewertet, was die Shorties zum Anlass nehmen um zu agieren. Heute soll nochmals eine Medienmitteilung von Hindenburg Research kommen, was Aphria angeht und angeblich hammermässig sein soll. Wer weiss, was da geschmiedet wird.


  • Ben - Du hast sicher noch einiges über APHRIA....ob Aurora auch noch Leichen im Keller hat?

    Aphria to review LATAM acquisition in face of 'inaccurate' allegations by short sellers

    [Blocked Image: https://s.yimg.com/it/api/res/1.2/s.6Q4JUzbbRHOlSecbrk8w--~A/YXBwaWQ9eW5ld3M7c209MTt3PTg0O2g9ODQ7aWw9cGxhbmU-/http://l.yimg.com/os/publish-images/finance/2016-03-04/b1d18a20-e20d-11e5-99a3-0b72938c288d_MWLOGO.jpg]

    Tomi Kilgore


    MarketWatchDecember 6, 2018

    Shares of Aphria Inc. sank 8.4% in premarket trade Thursday, after the Canada-based cannabis company said it has appointed a special committee to review its LATAM Holdings Inc. acquisition, which was completed in September. The shares had plummeted 43% over the past two sessions, closing Tuesday at a 17-month low, after short seller Quintessential Capital Management said Aphria's recent C$280 million Latin America acquisitions raised "major red flags," as its research suggested they appeared largely worthless, an allegation Aphria denied by saying it "unequivocally" stands behind the LATAM deal. On Thursday, the company said it remained confident in the process leading to the acquisition. "However, in the face of inaccurate and misleading accusations by certain short-sellers, whose sole interest is in profiting from a decline in the Company's shares, it is undertaking a comprehensive review, led by a Special Committee of independent directors of these, and any other, allegations in the interest of protecting Aphria shareholders," Aphria said in a statement. The stock had dropped 72.3% over the past three months, while the ETFMG Alternative Harvest ETF has shed 18.2% and the S&P 500 has lost 6.2%.

    Continue reading





    Aphria CEO fires back at short-sellers, vows 'our side of the story'

    David George-Cosh, BNN Bloomberg

    Aphria Inc. Chief Executive Officer Vic Neufeld is firing back at a short-sellers' report that has sent his company's shares into a tailspin, vowing to soon release more detailed information after the pot producer failed to ease investors' nerves with its initial response.

    In a phone interview with BNN Bloomberg, Neufeld said Aphria will soon provide a detailed, line-by-line response to the report released by Hindenburg Research and Quintessential Capital Management (QCM) on Monday that alleges the Leamington, Ont.-based company acquired assets in Jamaica, Argentina and Colombia worth a total of about $280 million at “vastly inflated” prices in a transaction the short-sellers claim benefited a group of insiders.

    "We need a complete rebuttal, not a piecemeal rebuttal. There’s lots of allegations of impropriety and we want our deck to speak on the facts," Neufeld said on Wednesday.

    In their report, QCM and Hindenburg Research allege that the foreign companies Aphria acquired in Jamaica, Argentina and Colombia appear to be “largely worthless” and that there were "systematic attempts to hide the true nature of these transactions." Both QCM and Hindenburg have taken short positions in Aphria, meaning they stand to benefit if its stock falls......


  • uff.....da kann man kaum durchblicken und nie weiss man sicher wer wirklich im Recht ist.

    Hier ein Interview:

    Aphria Report Is Not a Condemnation of Pot Sector, Short-Seller Grego Says

    Bloomberg Markets: The Close

    December 5th, 2018, 9:36 PM GMT+0100

    Gabriel Grego, Quintessential Capital Management founder, explains why he is short Aphria Inc. He speaks with Bloomberg's Caroline Hyde and Scarlet Fu on "Bloomberg Markets: The Close." (Source: Bloomberg)

    Aphria habe ich nicht - aber CRON hatte ein ähnliches Schicksal und Aurora ist ja auch nicht auf dem Höhenflug...ich weiss gar nicht ob es sich lohnt dem allen



  • Aurora-News

    Anbei mal wieder etwas Neues von ACB:


    Aurora Increases EU Footprint with Medical Cannabis Shipment to Luxembourg

    Receives Import and Export licenses and Commences Shipment to Luxembourg Market

    EDMONTON, Dec. 6, 2018 - Aurora Cannabis Inc. ("Aurora" or the "Company") (NYSE: ACB) (TSX: ACB) (Frankfurt: 21P; WKN: A1C4WM) announced today that the company, through its wholly owned subsidiary Aurora Europe GmbH, has been selected by the Luxembourg Health Ministry for the supply of medical cannabis to that country and an initial purchase order for approximately 20 kilograms has been received.

    The Company has received all required authorizations (import and export licenses) and has commenced its first shipment of high-grade medical cannabis to Luxembourg's Division de la Pharmacie et des Medicaments, representing the second time the Company has received an order directly from a European government.

    "To our knowledge, Aurora is the first medical cannabis producer selected by the Luxembourg Health Ministry to supply dried cannabis flower," said Neil Belot, Chief Global Business Development Officer. "This is a reflection of the trust we have earned with governments and regulators around the world. We look forward to supplying patients in need in what will be the 7th European Union member country where we have exported plants or products to help meet growing patient demand."

    Maximilian Weinberg Head of Business Development Aurora Europe GmbH, added, "Working directly with governments provides patients all over Europe the assurance that the medical cannabis products they consume meet the highest quality and safety standards. We are proud to be a trusted partner for both wholesalers and governments throughout Europe, and look forward to further increasing our footprint in this important growth market in which we have substantial early mover advantage."

    About Aurora

    Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 500,000 kg per annum and sales and operations in 22 countries across five continents, Aurora is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

    Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high quality product at low cost. Intended to be replicable and scalable globally, our production facilities are designed to produce cannabis of significant scale, with high quality, industry-leading yields, and low per gram production costs. Each of Aurora's facilities is built to meet EU GMP standards, and its first production facility, the recently acquired MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland, have achieved this level of certification.

    In addition to Aurora's rapid organic growth and strong execution on strategic M&A, which to date includes 15 wholly owned subsidiary companies – MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia Labs, HotHouse Consulting, MED Colombia, Agropro, Borela, and ICC – Aurora is distinguished by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Capcium Inc. (private), Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), and Alcanna Inc. (TSX: CLIQ).

    Aurora's Common Shares trade on the TSX and NYSE under the symbol "ACB", and are a constituent of the S&P/TSX Composite Index.

    For more information about Aurora, please visit our investor website, investor.auroramj.com

    Terry Booth, CEO
    Aurora Cannabis Inc.

    Caution Concerning Forward-Looking Statements

    This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur and include, but are not limited to the variety of cannabis products that Aurora will supply to the adult use market.. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

    Neither the TSX, NYSE nor their Regulation Services Provider (as that term is defined in the policies of the TSX and NYSE) accepts responsibility for the adequacy or accuracy of this release.

    SOURCE Aurora Cannabis Inc.

    [Blocked Image: https://rt.newswire.ca/rt.gif?NewsItemId=C7790&Transmission_Id=201812061330CANADANWCANADAPR_C7790&DateId=20181206]

    For further information: For Media: Heather MacGregor, (416) 509-5416, heather.macgregor@auroramj.com; For Investors: Marc Lakmaaker, (647) 269-5523, marc.lakmaaker@auroramj.com; Rob Kelly, (647) 331-7228, rob.kelly@auroramj.com; U.S. Investors: Phil Carlson / Elizabeth Barker, KCSA Strategic Communications, (212) 896-1233 / (212) 896-1203, pcarlson@kcsa.com / ebarker@kcsa.com

    [Blocked Image: https://gallery.mailchimp.com/4fd18cec8f6ff2fc8bf9e921b/images/2a5fef98-d4a1-44c5-989e-2ed0cf2ce88a.png]

    [Blocked Image: https://cdn-images.mailchimp.com/icons/social-block-v2/color-twitter-48.png]

    [Blocked Image: https://cdn-images.mailchimp.com/icons/social-block-v2/color-facebook-48.png]

    [Blocked Image: https://cdn-images.mailchimp.com/icons/social-block-v2/color-link-48.png]

    Copyright © 2018 Aurora Cannabis Inc, All rights reserved.

    Our mailing address is:
    1500 - 1199 W. Hastings St. Vancouver BC V6E 3T5

    Want to change how you receive these emails?
    You can update your preferences or unsubscribe from this list

  • Cannabis Roundup: DAVIDsTEA Preps Earnings, Aurora Cannabis Tumbles

    Wall Street is expecting good things from DAVIDsTEA's earnings after the closing bell, sending the stock soaring.

    Tony Owusu

    Dec 13, 2018 12:45 PM EST

    Pot stocks have had a rocky fourth quarter, with the ETFMG Alternative Harvest ETF (MJ - Get Report) falling 25% over the past three months.

    That trend continued Thursday with the largest pot ETF by net asset value falling 1.6%. Alternative Harvest has had a rough fourth quarter since reaching a year-to-date high of up 32% in September.

    The industry may be suffering from the bubble that inflated earlier this year as investors overvalued many of the stocks in the sector.

    The pot industry, however, got some good news after Congress passed the 2018 Farm Bill, which legalizes the cultivation and farming of hemp, which contains cannabidiol (CBD), the non-psychoactive chemical compound found in cannabis.

    Shares of New Age Beverages Corp. (NBEV - Get Report) , which manufactures CBD-infused drinks, jumped more than 11% on the news before pairing all of its gains amid a market selloff.

    DAVIDsTEA Inc. (DTEA - Get Report) shares were up 6% ahead of the company's earnings release after Thursday's closing bell.

    India Globalization Capital Inc. (IGCC - Get Report) jumped 4% on the CBD news.

    Other stocks in the sector traded lower Thursday.

    Aurora Cannabis Inc. (ACB - Get Report) shares fell more than than 6% after the company invested $10 million in High Tide, a Canadian cannabis retailer that Aurora says is "developing an expanding network across Canada of cannabis and cannabis accessory retail stores."

    Shares of Tilray Inc. (TLRY) were down 10% despite the news that the California Public Employees' Retirement System, the biggest pension fund in the country, owned 1,617 shares of the Canadian cannabis company.

    Canopy Growth Corp. (CGC) declined 3.4%, while Cronos Group Inc. (CRON) and Aphria Inc. (APHA) dropped 5.5% and 8%, respectively.


    ....nicht so toll

  • Infos

    *smile* *dirol* Da sollte man wohl in der Branche mindestens mit einem Bein drin sein / bleiben:

    HINTERGRUND-Nach der Potcom-Blase - Cannabis-Branche wird erwachsen 19-12-2018 15:29

    * Cannabis-Branche wächst dank zunehmender Legalisierung

    * Getränke- und Tabakindustrie investiert Milliarden

    * Aktien sind nach Rekordwerten im Herbst aber auf Talfahrt

    - von Patricia Weiss

    Frankfurt, 19. Dez (Reuters) - In der Cannabis-Branche herrscht Goldgräberstimmung. Anleger, die ihr Geld in börsennotierte Produzenten wie Canopy Growth und Aurora Cannabis steckten, konnten sich in den vergangenen zwei Jahren eine goldene Nase verdienen. Inzwischen ist etwas Ernüchterung eingekehrt: Seit Kanada im Oktober als weltweit erste große Industrienation den Cannabis-Konsum vollständig freigab, gingen die Kurse nach unten, auch wegen schwächer als erwarteter Geschäftszahlen. "Die Aktien waren ein absoluter Spielball von Zockern", sagt Analyst Jochen Stanzl vom Broker CMC Markets. Dieser Hype sei vorbei. "Die Frage ist nun, wie sich die Unternehmen dieser Branche etablieren." Denn auch wenn sich Anleger 2019 dem nächsten Trendthema zuwenden dürften, sind sich Experten einig: Die Cannabis-Industrie ist auf Wachstumskurs, die Nachfrage ist riesig - als Genussmittel sowieso, aber immer mehr auch zu medizinischen Zwecken.

    Seit Anfang 2017 bis zu den Höchstständen im Oktober dieses Jahres legten die Aktien von Branchengrößen wie Canopy Growth und Aurora Cannabis um 670 Prozent beziehungsweise 650 Prozent zu. Seitdem haben die Aktien der Cannabis-Firmen an der Börse aber teilweise mehr als die Hälfte an Wert eingebüßt. Der nordamerikanische "Marijuana Index", in dem die führenden Unternehmen der Branche aus den USA und Kanada gelistet sind, hat seit seinem Rekordhoch im Herbst rund die Hälfte verloren. CMC-Analyst Stanzl spricht von einer Blase, die geplatzt ist. "Von der Psychologie war das vergleichbar mit Bitcoin." Für einen digitalen Taler mussten Anleger vor einem Jahr knapp 20.000 Dollar auf den Tisch legen, inzwischen kostet Bitcoin gerade noch 3200 Dollar.

    Einig sind sich Experten aber, dass es sich bei Cannabis im Gegensatz zum Bitcoin um ein echtes Produkt mit großem Marktpotenzial handelt. "Bei den großen kanadischen Herstellern haben wir erstaunliche Wachstumsraten gesehen. Das wird in der Geschwindigkeit möglicherweise nicht so weitergehen, aber es wird aus meiner Sicht zu weiterem signifikantem Wachstum kommen", sagt Peter Homberg, Partner und Leiter der Life-Science-Praxis bei der Wirtschaftskanzlei Dentons.

    Auch Marktforscher zeichnen ein positives Bild und überbieten sich in ihren euphorischen Prognosen: Bis 2022 dürften die weltweiten Ausgaben für legales Marihuana nach Einschätzung von BDS Analytics und Arcview auf 32 Milliarden Dollar steigen, 2017 waren es noch 9,5 Milliarden. 41 Prozent dürften bis dahin alleine auf Kanada und Kalifornien entfallen. Kalifornien zählt zu einer Reihe von US-Bundesstaaten von Colorado bis Washington, in dem der Cannabis-Konsum bereits vollständig legal ist. Aber auch Europa spielt eine immer wichtigere Rolle. Dort erlauben mehr als 20 Länder medizinisches Cannabis, darunter Deutschland seit März 2017. Die Marktforscher von Prohibition Partners trauen alleine Europa bis 2028 ein Marktpotenzial von knapp 116 Milliarden Euro (knapp 132 Milliarden Dollar) zu. Das setzt allerdings eine vollständige und eher unwahrscheinliche Legalisierung auf dem gesamten Kontinent voraus.


    Welche Unternehmen können am meisten Geschäft abschöpfen? Zu den Erfolgsfaktoren zählen nach Einschätzung der Analysten der Berenberg Bank Größe, Produktvielfalt, Marken sowie der Marktzugang. Dabei sehen sie Canopy Growth am besten positioniert, sowohl auf dem Heimatmarkt Kanada als auch international. Das Unternehmen hat zudem einen starken Partner im Rücken: Der Corona-Bier-Hersteller Constellation Brands pumpte im August vier Milliarden Dollar in Conopy und baute seinen Anteil auf 38 Prozent aus. Zusammen wollen die beiden Firmen cannabishaltige Getränke entwickeln - ein Trend, den auch Coca Cola nach eigenen Angaben genau beobachtet. Dem weltgrößten Getränkekonzern wurde Interesse am Canopy-Rivalen Aurora nachgesagt. Einen Schritt weiter ist bereits der Tabakkonzern Altria. Der Marlboro-Hersteller stieg kürzlich bei dem kanadischen Produzenten Cronos für 1,8 Milliarden Dollar ein.

    Während Nordamerika bei der Legalisierung von Cannabis als Genussmittel eine Vorreiterrolle einnimmt, steht in Europa die Freigabe zu medizinischen Zwecken im Fokus. Erst im November legalisierte Großbritannien medizinisches Cannabis. Die Wirkstoffe können unter anderem Schmerzen bei Krebserkrankungen, Übelkeit nach Chemotherapien oder Spastiken bei Multipler Sklerose lindern. "Wir sehen eine starke Entwicklung hin zur medizinischen Verwendung in allen möglichen Ländern, das ist ein riesiges Potenzial", ist sich Georg Wurth, Geschäftsführer beim Deutschen Hanfverband, sicher. Nach seinen Schätzungen gibt es in Deutschland rund 30.000 Patienten, die Cannabis von der gesetzlichen Krankenkasse erstattet bekommen, Tendenz steigend. Bislang wird der hiesige Bedarf noch über Importe gedeckt. Erst ab 2020 dürfte nach Einschätzung des Bundesinstitut für Arzneimittel und Medizinprodukte Cannabis auch aus Anbau in Deutschland zur Verfügung stehen. Das Institut hat Aufträge zur Produktion von medizinischem Cannabis in Deutschland ausgeschrieben, die Bewerbungsfrist dafür endete erst vor wenigen Tagen.

    (Mitarbeit von Patricia Uhlig, redigiert von Kathrin Jones. Bei Rückfragen wenden Sie sich bitte an die Redaktionsleitung unter den Telefonnummern 069-7565 1232 oder 030-2888 5168.) ((patricia.weiss@thomsonreuters.com; +49 69 7565 1337; Reuters Messaging: patricia.weiss.reuters.com@reuters.net, http://www.twitter.com/REUTERS_DE, http://www.reuters.de))

    [Blocked Image: https://premium.swissquote.ch/gifs/logo_thomson_reuters.gif]

    Quelle Swissquote

  • Trump Signs 2018 Farm Bill


    Chuck Abbott


    Michael Vadon

    President Trump signed into law the 2018 farm bill that modestly strengthens the farm safety net, loosens farm subsidy rules, and legalizes industrial hemp as a crop and then announced he was taking “immediate action on welfare reform” through stricter enforcement of time limits on food stamps to able-bodied people on Thursday.....


    ...ist schon nicht so prickelnd - sobald es legal wird sausen die Aktien runter, war in Kanada auch so

  • Aurora & Co.

    Canada's pot shortage could last up to 3 years, executives warn

    Kristine Owram, Bloomberg News

    Canada’s pot shortage could last as long as three years, according to industry executives who say production estimates are too rosy.

    Shortages have plagued the country since recreational marijuana was legalized in October. In response, Quebec’s government-controlled stores have closed three days a week, Alberta has temporarily stopped issuing retail licenses and Ontario has said it will initially open just 25 stores across Canada’s most populous province....

    ......Aurora Cannabis Inc. said Tuesday it expects to report fiscal second-quarter revenue of $50 million to $55 million, below the consensus estimate of $67.4 million. Aurora fell 4.1 per cent to $6.71 in Toronto at 11 a.m.


  • APHRIA & Co.

    News: Vic Neufeld ist nicht mehr CEO von Aphria. Er ist nun weg.

    Heute werden die Q2 Zahlen präsentiert. Es wird bzw ist spannend.

    Also, ich hoffe, dass der Zahlenkranz gut ausfällt und der Kurs sich in Richtung Norden bewegt.

    (Ich habe kürzlich in einem YellowPress Magazin gelesen, dass New York City sich gedanken über die Legalisierung von Cann macht. Natürlich geht es um Steuereinnahmen, mit denen man dann die marode Subway modernisieren würde. Nice.) Yes, Cann can.

  • Tilray Surges After Privateer Holdings Vows to Hold Stake Until At Least H2 2019

    [Blocked Image: https://s.yimg.com/it/api/res/1.2/WTkHbRvVY8WdHjtGJnT13g--~A/YXBwaWQ9eW5ld3M7c209MTt3PTg0O2g9ODQ-/http://media.zenfs.com/284/2011/06/08/thestreet-106x27_153053.gif]

    Martin Baccardax


    TheStreet.comJanuary 11, 2019

    Privateer Holdings, a a Seattle-based private equity group that limits its investments to the cannabis industry that owns an estimated 76% of Tilary's outstanding shares, said it has a strong belief in Tilray's long-term global growth strategy and its "pioneering role" in shaping the future of the legal marijuana market. "We do not have plans to register, sell or distribute the shares Privateer holds in Tilray during the first half of 2019," Privateer managing partner Michael Blue said in a statement. "When we decide to distribute shares, we will do so in an orderly and deliberate manner to maximize tax-efficiency considerations for Privateer investors, while also taking into consideration potential impacts on Tilray's public float....


    .....das tut der ganzen Branche gut!

  • GreenGrowGrass

    Tilray mit über 22% im Plus und Aphria mit über 8,8%. Vic Neufeld räumt als CEO das Feld und Jacob Riphstein Ex-Diageo übernimmt mit neu ausgerichtetem Management. Nach dem ganzen Hindenburg und Shortsellingdrama im Dezember, wird einiges in Bewegung kommen.

    Have a nice WE.

  • New Age Beverages

    Why New Age Beverages Stock Soared 140% in 2018

    [Blocked Image: https://s.yimg.com/it/api/res/1.2/LSNIDeN7bq1_gJWbIvMgpQ--~A/YXBwaWQ9eW5ld3M7c209MTt3PTg0O2g9ODQ7aWw9cGxhbmU-/http://l.yimg.com/os/creatr-images/GLB/2017-10-10/7992db30-ae00-11e7-987d-519fbcf9902a_MotleyFool2.png.cf.jpg]

    Beth McKenna, The Motley Fool


    Motley FoolJanuary 14, 2019

    What happened

    New Age Beverages (NASDAQ: NBEV) stock gained 140% last year, according to data from S&P Global Market Intelligence. For context, the S&P 500 declined 4.4% (including dividends)....


  • Aurora to Acquire Whistler

    Canada NewsWire 1 day ago

    Aurora Cannabis Inc. said Monday it intends to acquire the one of the last independent members of the so-called “blessed eight,” a group of marijuana companies given the first approval to move cannabis genetics from the black market into the legal regime.

    Aurora ACB, +10.29% ACB, +8.33% said it would pay up to C$175 million ($132 million) in stock for Whistler Medical Marijuana Corp., a privately held British Columbia-based producer of cannabis, which is known in Canada for its ability to produce organic cannabis. “I would call [Whistler] the crown jewel of organic cannabis production world-wide,” Aurora Chief Corporate Officer Cam Battley said in a phone interview. “It’s the first organic-certified company, and now we’ve essentially got the market to ourselves.”

    Battley said Whistler will help with its near-term strategy of growing cannabis itself until the company is able to secure high-quality product from suppliers at a low enough price, which at the moment isn’t possible.

    TimeAurora Cannabis Inc.Mar 18May 18Jul 18Sep 18Nov 18Jan 19



    As recreational cannabis legalization has kicked off, consumers have faced a confusing swath of products to choose from, said Rebecca Brown, chief executive of the cannabis ad firm Crowns Agency. “It’s hard for people to decode who is who, what is what,” she said. “It’s a good buy for Aurora because it gives them an ability to make the kind of differentiated claim people are familiar with.”......


  • Info vom letzten Freitag: Die Wandlersache sollte eigentlich nicht schaden. Wurde ja von CGC auch schon so gemacht...

    Was meint ihr dazu? Sind ja nur $300M

    Aurora arranges $300M (U.S.) note financing

    2019-01-18 07:55 ET - News Release

    Mr. Terry Booth reports


    Aurora Cannabis Inc. has priced its previously announced offering of convertible senior notes due 2024. The company will issue $300.0-million (U.S.) aggregate principal amount of notes, or $345.0-million (U.S.) aggregate principal amount if the initial purchasers' overallotment option is exercised in full. The notes will be issued at par value.

    Aurora expects to use the net proceeds from the offering of the notes to support its Canadian and international expansion initiatives, for future acquisitions and for general corporate purposes, including working capital requirements to continue the company's accelerated growth.

    The notes will be unsecured and will mature on Feb. 28, 2024. The notes will bear cash interest semi-annually at a rate of 5.5 per cent per annum. The initial conversion rate for the notes will be 138.37 common shares per $1,000 (U.S.) principal amount of notes, equivalent to an initial conversion price of approximately $7.23 (U.S.) per common share. The initial conversion rate represents a premium of approximately 10.0 per cent to yesterday's common share closing sale price on the New York Stock Exchange and is subject to adjustment in certain events.

    Upon conversion, the notes will be settled in cash, Aurora common shares or a combination of cash and Aurora common shares, at Aurora's election. Aurora will have the right to redeem the notes in certain circumstances after Feb. 28, 2022, at a redemption price equal to 100 per cent of the principal amount of the notes to be redeemed, plus accrued and unpaid interest. Holders will also have the right to require Aurora to repurchase their notes upon the occurrence of certain customary events at a purchase price equal to 100 per cent of the principal amount of the notes to be repurchased, plus accrued and unpaid interest.

    The offering of notes is expected to close on or about Jan. 24, 2019, subject to customary closing conditions. This announcement is neither an offer to sell nor a solicitation of an offer to buy the notes or the common shares of Aurora into which the notes are convertible and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.

    About Aurora Cannabis Inc.

    Headquartered in Edmonton, Alta., Canada, with financed capacity in excess of 500,000 kilograms per annum and sales and operations in 22 countries across five continents, Aurora is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

    We seek Safe Harbor.

    © 2019 Canjex Publishing Ltd. All rights reserved.

  • Aurora @ Lorenz

    ...sollte nicht - Aurora hat aber doch Schönheitsfehler momentan:

    Midas Letter - video

    External Content www.youtube.com
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.


    The 300 milliy is the best deal they have done in a while but is still contains that option to dilute. The market simply doesn't trust these two. Even if they make a good deal they have so many others that have yet to be proven. This the problem. Their history says everything is dilutive. Their new claim to be in assembly mode is only a claim and contradicts their actions. We haven't seen any of that yet. All we have is Cam saying "next quarter".

    Is SKY fully functional yet?

    Read more at http://www.stockhouse.com/comp…board#hh4fzjJpa2liczBM.99

    RE:RE:Aurora Short Positions Increase by 53.56%

    Stockemups wrote:

    Read more at http://www.stockhouse.com/comp…board#U8UOLCvRSMok0wO5.99